Navigation Links
Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
Date:5/15/2008

could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligati
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Pfenex Inc. (NYSE MKT: PFNX), ... high-value and difficult to manufacture proteins including biosimilar therapeutics, ... 21 st Annual NewsMakers in the Biotech Industry ... Bertrand Liang , chief executive officer of Pfenex, will ... business strategy on Friday, September 26, 2014 at 10:00 ...
(Date:9/19/2014)... 19, 2014 ... ) has announced the addition of the  "Micro ... to their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... of the fastest-growing segments in the chromatography market. ... 2013, and expected to reach $2.0 billion by ...
(Date:9/18/2014)... Austin, TX (PRWEB) September 18, 2014 ... of integrated urological and interventional radiology products and ... (also known as cryotherapy and cryoablation) versus external ... Mid-Atlantic Section of the American Urological Association (MAAUA) ... , "Comparing Relative Effectiveness of Cryosurgery and ...
(Date:9/18/2014)... KEEGO HARBOR, Mich. , Sept. 18, 2014  Health ... -based biotech firm investigating early-stage algae bioactive compounds and metabolic ... member to the company,s board of directors. Ms. Nola ... executive and investment advisor joined the board effective September 17, ... have Ms. Masterson agree to join our board," states ...
Breaking Biology Technology:Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2
... Oct. 13 This afternoon, Fraunhofer USA, Inc.,s ... its first laboratory, a PV module innovation facility ... Ambassador Klaus Scharioth and Massachusetts Energy Secretary Bowles. ... , The new PV module laboratory enables research, ...
... and MIAMI, Oct. 13 The Alpha-1 Foundation announced ... study how genetic variations in the alpha-1 antitrypsin (AAT) ... with AAT deficiency. The inherited condition causes emphysema and ... infusion therapy -- known as augmentation therapy -- minimizes ...
... 13 Advanced Life Sciences Holdings, Inc. (OTC ... the discovery, development and commercialization of novel drugs ... respiratory diseases, today announced that it will present ... in San Francisco. , (Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO ...
Cached Biology Technology:Fraunhofer CSE Opens First Laboratory in Cambridge, MA 2Fraunhofer CSE Opens First Laboratory in Cambridge, MA 3The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc. 2The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc. 3The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc. 4Advanced Life Sciences to Present at 8th Annual BIO Investor Forum 2
(Date:9/18/2014)... Elsevier, a world-leading provider of scientific, technical ... Australasian Research Management Society (ARMS), recognized the academic ... 5th Scopus Young Researcher of the Year Awards. ... the National Convention Centre and in conjunction with ... guests representing Australia,s and New Zealand,s scientific community. ...
(Date:9/18/2014)... world, are the ideal animal in which to study ... the ocean into tens of thousands of freshwater streams ... skeleton to adapt to the new environment. , Breeding ... have turned up one of the genes that controls ... that gene,s regulation in a freshwater population is associated ...
(Date:9/18/2014)... swim up to 400 kilometres in search of a home, ... , Clownfish spend their entire adult lives under the protection ... the open ocean, says study co-author, Dr Hugo Harrison from ... CoE) at James Cook University. , "In the past we ... a rare glimpse into how far they can swim, crossing ...
Breaking Biology News(10 mins):Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Nemo's epic journey to find a new home 2
... over global warming and instead reduce fossil-fuel use for the ... scientists, one from the University of Washington and one from ... in the current issue of the journal Nature ... supply will trump the environment as a reason to curb ...
... Irvine, Calif., Jan. 26, 2012 Location matters for ... UC Irvine and Wesleyan University. Findings suggest that chickadees and ... as the characteristics of their wriggly prey. Unfortunately for ... can dramatically boost their own risk of becoming food. Study ...
... for breast cancer research as well as basic cell ... Lawrence Berkeley National Laboratory (Berkeley Lab) have discovered a ... ability of breast cells to form the spherical structures ... which the researchers call "CAMo," for coherent angular motion, ...
Cached Biology News:Commentary in Nature: Can economy bear what oil prices have in store? 2Commentary in Nature: Can economy bear what oil prices have in store? 3For the birds 2Berkeley Lab researchers discover critical rotational motion in cells 2Berkeley Lab researchers discover critical rotational motion in cells 3Berkeley Lab researchers discover critical rotational motion in cells 4
Request Info...
... (YELLOW), 1 EA. Ultrospec 6300 ... requirements of the Pharmacopoeia in terms of ... benefits of being able to be used ... nm and excellent scanning capability., *Press to ...
... Labeling Kit, 1 kit. Convenient ... dyes. Conjugations are carried out under ... h. Dyes are packaged in premeasured ... labelings. Category: Blotting & Labeling & ...
nucleophosmin (nucleolar phosphoprotein B23, numatrin), mRNA...
Biology Products: